Area 3

Inflammatory bowel disease (IBD)

Team leader

Strategic objectives

This IDIBAPS research team has a translational orientation, aimed at generating knowledge in the area of inflammatory bowel diseases to provide a direct benefit to patients suffering from Crohn’s disease or ulcerative colitis in the near future. The team’s research plan includes three main strategic objectives:

  • The development of new treatments for Crohn’s disease and ulcerative colitis, focused on celltherapy and the identification of new therapeutic targets susceptible to pharmacological modulation.
  • Further in-depth knowledge of the genetic and environmental factors responsible for susceptibility and the course of the disease, with a view to designing personalized therapies.
  • Optimization of the radiological and biochemical diagnostic techniques with the aim of adapting treatment to the needs of each individual patient.

Main lines of research

  1. Hematopoietic stem cell autotransplantation in refractory Crohn’s disease. Characterization of host and intestinal microbiota related factors in the therapeutic response.
  2. Evaluation of the efficacy and safety of treatment with autologous tolerogenic dendritic cells derived from peripheral blood monocytes in refractory Crohn’s disease.
  3. Development and optimization of intestinal epithelial stem cells production. Evaluation of the therapeutic potential of intestinal stem cell transplantation in severe Crohn’s disease and ulcerative colitis.
  4. Optimization of cross sectional imaging techniques, for evaluation of the extent, severity and prognosis of the inflammatory lesions in Crohn’s disease and ulcerative colitis.
  5. Advanced endoscopic techniques for diagnosis and treatment of IBD.